Triple-negative breast cancer.

By W. Foulkes, I. Smith, J. Reis-Filho. New England Journal of Medicine, 2010

1,950 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/26e0ab11318d28d5b8be8156d94ee61f2397654b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Balázs Győrffy
2. N. Almansour

In Oncology

1. N. Almansour
2. Balázs Győrffy

In Pulmonary and Respiratory Medicine

1. Balázs Győrffy
2. N. Almansour

Citations in the corpus

• Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis (2018, neutral): “Such accurate assessment is crucial to avoid false diagnosis of ERnegative and/or HER2-negative disease in patients that would be benefited from endocrine therapy and/or HER2targeted drugs.(285,286) TNBC clinical phenotype usually consists of the basal-like molecular subtype, although TNBC and basal”
• miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis (2020, methodology): “miR-4417 Breast Cancer Downregulated Prognostic tool for TNBC Levels correlated to the evolution of the disease [52,131]”
• Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer (2021, background): “Today, basal cases have the worst expected outcome with high risk of relapse within a few years following diagnosis [5].”
• Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence (2022, background): “Scientifically, this cancer is categorized as a distant subgroup within a broad category of breast cancers (Foulkes et al., 2010).”
• Breast Cancer Treatment: A Review (2019, background): “Score categoryb Low (≤10) Intermediate (11-25) Intermediate (11-25) High (≥26) Low (≤11) Lowintermediate (≤25) High (≥26) Clinical high risk/ MammaPrint low risk Clinical high risk/ MammaPrint low risk”